Skip to main content

Peer Review reports

From: Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease

Original Submission
6 May 2014 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Resubmission - Version 5
Submitted Manuscript version 5
Author responded Author comments
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
29 Jan 2015 Editorially accepted
8 Mar 2015 Article published 10.1186/s12886-015-0001-7

You can find further information about peer review here.

Back to article page